within Pharmacolibrary.Drugs.N_NervousSystem.N02B_OtherAnalgesicsAndAntipyretics.N02BB52_MetamizoleSodiumCombinationsExcl;

model MetamizoleSodiumCombinationsExcl
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.85,
    Cl = 3.333333333333333e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.03,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007500000000000001,
    Tlag = 600);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>MetamizoleSodiumCombinationsExclPsycholeptics</td></tr><tr><td>ATC code:</td><td>N02BB52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metamizole sodium, also known as dipyrone, is a non-opioid analgesic, antipyretic, and spasmolytic drug used for the relief of severe pain and fever. It is typically employed as a second-line medication when other non-opioid analgesics are insufficient. While widely used in some countries, it has been withdrawn or restricted in several due to risks of agranulocytosis.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult population. No specific published data for the pharmacokinetics of metamizole combinations (excl. psycholeptics; ATC N02BB52); parameters for metamizole sodium alone extrapolated for oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02BB52 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetamizoleSodiumCombinationsExcl;
